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UMBILICAL CORD BLOOD TRANSPLANTATION: STATE OF THE ART
Wagner, John E. Blood and Marrow Transplantation Program and
Stem Cell Institute, University of Minnesota, Minneapolis, MN.
Cryopreserved umbilical cord blood (UCB) has been investigated as
a potential strategy for augmenting the pool of acceptable donors,
reducing the risks of acute and chronic graft-versus-host disease
(GVHD) and improving survival. Cell dose, however, has clearly been
established as the most signiﬁcant limitation. To this end, multiple
strategies have been proposed to address cell dose, including use of
culture expanded UCB, co-infusion of haploidentical peripheral
blood, multiple units, co-infusion of mesenchymal stem cells, and
intra bone marrow injection. In addition, novel strategies to reduce
regimen related mortality (RRM) and enhance graft-versus-leukemia
have been explored. In anticipation of these presentations, the ex-
pected outcomes with the standard approach of myeloablation and
single UCB transplantation will be summarized.
At the University of Minnesota, 102 patients received cyclophos-
phamide 120 mg/kg, total body irradiation 1320-1375 cGy and
antithymocyte globulin 90 mg/kg with cyclosporine and short
course methylprednisolone immunoprophylaxis. Median age was
7.4 years and median cell dose was 3.1  107 nucleated cells/kg
(range 0.7-57.9) with 86% receiving a 1-3 HLA-antigen mis-
matched graft. Median time to neutrophil recovery was 23 days
(range 9-54) with 88% engrafting by day 42. Inferior engraftment
was observed in patients receiving a CD34 cell dose 1.7  105
cells/kg (72% at a median of 34 days). Incidence of grade II-IV and
grade III-IV acute GVHD was 39% (95% CI: 29-49) and 11%
(95% CI: 5-17), respectively, and incidence of chronic GVHD was
10% (95% CI: 4-14). RRM at 1 year was 30% (95% CI: 21-39)
with low CD34 cell dose and HLA disparity adversely affecting
outcome. At a median of 2.7 years, survival was 58% (95% CI:
49-70) at 1 year and 47% (95% CI: 36-57) at 2 years with 70%
(95% CI: 49-90) survival in patients receiving 1.7  105 CD34
cells/kg. In Cox regression, HLA match, CD34 cell dose and
development of grade III-IV acute GVHD risk factors. These data
highlight the limitations of UCB and serve to stimulate the next
generation of clinical trials.
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REDUCED-INTENSITY UNRELATED CORD BLOOD TRANSPLANTATION
FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Miyakoshi, Shigesaburo. Department or Hematology, Toranomon Hos-
pital, Tokyo, Japan.
Allogeneic stem cell transplantations (SCT) have been develop-
ing rapidly. Graft versus malignancy is the therapeutic component
of SCT so that myeloablation is not absolutely essential. Non-
myeloablative stem cell transplantation and transplantation with
reduced intensity (RI) conditioning have been developed. Eventu-
ally, we can combine many kinds of stem cell sources and condi-
tioning regimens.
In 2001 the clinical outcome of 2 patients with malignant lym-
phoma after reduced intensity stem cell transplantation (RIST)
with cord blood (RICBT) was ﬁrst reported by investigators at
Duke University. After this, several reports about RICBT were
published. These reports encouraged us to start RICBT. We have
already acquired valuable experience about RICBT for hemato-
logic malignancies.
In this symposium the results of RICBT for hematologic malig-
nancies in Toranomon Hospital will be summarized.
In our experience, this reduced intensity regimen and graft-
versus-host disease (GVHD) prophylaxis were almost certain to
lead to neutrophil, platelet and donor T cells engraftment. Inci-
dence of acute/chronic GVHD and overall survival (OS) were
acceptable, however treatment related mortality (TRM) was high.
Second, I will report the results of RICBT for adult acute lym-
phoblastic leukemia (ALL) and relapsed and refractory malignant
lymphomas (ML). As a matter of course OS and disease free
survival (DFS) were not so good, but RICBT would lead some
patients to cure. RICBT would be one of the strategies for cure of
ALL and ML. However, TRM after RICBT was the most impor-
tant problem for ML and ALL.
Third, I compared among related peripheral blood stem cell
transplantation (R-PBSCT), unrelated bone marrow transplanta-
tion (UBMT), and cord blood transplantation with reduced inten-
sity regimens for AM/MDS. The incidence of acute GVHD,
TRM, and OS were similar among these three stem cell sources
with reduced intensity regimens, but neutrophil and platelet en-
graftment were slower than R-PBSCT. Relapse rate over 100 days
in RICBT might be higher than for the others.
Finally, I will conclude that the most important problem after
RICBT is high TRM. We should consider new approaches to
decrease TRM after RICBT.
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REDUCED INTENSITY (RI) ALLOGENEIC CORD BLOOD HEMATOPOI-
ETIC CELL TRANSPLANTATION (ALLO-CBHCT) IN PEDIATRIC PATIENTS
WITH MALIGNANT AND NON-MALIGNANT DISEASES
Satwani, P.,1 Del Toro, G.,1 Bradley, M.,1 Morris, E.,1 van de Ven, C.,1
Cheung, Y.-K.,2 Yamashiro, D.,1 Garvin, J.,1 Bhatia, M.,1 Roman, E.,1
Schwartz, J.,3 Militano, O.,1 Cooney, E.,1 Wolownik, K.,1 Hawks, R.,1
Foley, S.,1 Cairo, M.S.1,3,4 Departments of 1Pediatrics, 2Biostatistics,
3Pathology, and 4Medicine, Columbia University, New York, NY.
There is a signiﬁcant amount of morbidity and mortality following
myeloablative CBHCT (Gluckman et al, NEJM 1997). RI condition-
ing may reduce regimen-related mortality (RRM) and the late effects
associated with myeloablative regimens without increasing the risk of
graft failure in children and adolescents (Del Toro et al, BMT 2004).
We report the results in 22 pediatric recipients, 6F:16M, median age
6.5 years (0.4-21 yrs). Twenty one received unrelated CBHCT, with
HLA matching of 4/6 (n  14), 5/6 (n  5), 6/6 (n  2); 1 sibling
CBHCT (6/6). Seventeen hadmalignant [HD (5), NHL (2), NBL (4),
AML (2), MDS(3), CML (1)], and 5 had non-malignant [-thal (1),
HLH (2), WAS (1), SCD (1)] diseases. RI conditioning was ﬂudara-
bine-based (150-180 mg/m2) with busulfan (8 mg/kg)  rabbit ATG
(n 17) and ﬂudarabine cyclophosphamide etoposideATG (n
 5). GHVD prophylaxis: tacrolimus and MMF (Osunkwo et al,
BBMT 2004). Median TNC count was 3.8 107/kg (0.92-10.82) and
CD34 count was 2.2  105/kg (0.34-7.0). The median day to WBC
engraftment was 19.5 (1-47) and to platelet engraftment was 40
(6-170) days. There were 6 primary graft failures (1 CML, 1 -Thal,
2 HLH, 1 MDS, 1 AML).The probability of developing grade II-IV
and III-IV aGVHD was 33.3% and 15%, respectively, and probability
of chronic GVHD was 20%. The probability of 3-year overall OS in
all patients was 63%. Despite a log less nucleated cells/kg with CB vs
PB or BM HCT, the 3-yr OS in standard-risk malignancy patients
was 90%. The 1-yr OS in poor-risk malignancy patients was 21%. In
conclusion, RI Allo CBHCT may result in more rapid hematopoietic
reconstitution while decreasing RRM compared to myeloablative CB-
HCT and may be associated with high mixed-donor chimerism.
Patients with non-malignant diseases may require increased intensity
of conditioning. Further follow-up is required to evaluate the long-
term effects following RI Allo-CBHCT.
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DOUBLE UMBILICAL CORD TRANSPLANTS (UCBT) WITH MYELOABLA-
TIVE OR REDUCED INTENSITY CONDITIONING REGIMENS (RIC)
Baker, K. Scott, Wagner, John E. Blood and Marrow Transplantation
Program and Stem Cell Institute, University of Minnesota, Minne-
apolis, MN.
Between 2000 and 2005, 143 consecutive patients received two
partially HLA matched UCB units to enhance engraftment. 50
patients [median age: 24 years (range: 11-60 years)] received cy-
clophosphamide (CY) 120 mg/kg, TBI 1320 cGy and ﬂudarabine
1218
75 mg/m2 with GVHD prophylaxis of cyclosporin (CSA) and
mycophenolate (MMF). The median nucleated cell (NC) dose was
3.5  107/kg, 60% were 4/6 HLA mismatched. Sustained donor
engraftment was seen in 88% (95% CI: 83-97) at a median of 24
days. Complete donor chimerism was derived from one unit by day
60 in all but 4 patients. The incidence of grade III-IV acute
GVHD was 17% and chronic GVHD was 20%; TRM at 6 months
was 22%. With a median follow-up of 20 months, 2 yr survival and
DFS was 63% and 59%. 93 patients (median age: 52 years (range:
17-69) who were aged 45 or had preexisting co-morbidities
received non-myeloablative conditioning with CY 50 mg/kg, FLU
200 mg/m2/day and TBI 200 cGy followed by double UCBT.
GVHD prophylaxis also consisted of CSA and MMF. The median
NC dose was 3.7  107/kg with 61% having at least one 4/6 HLA
mismatched unit. Sustained donor engraftment was seen in 83% at
a median of 12 days with donor chimerism 90% by day 100. The
incidence of grade III-IV acute GVHD, CGVHD and TRM was
23%, 22%, and 15%, respectively. Probability of DFS at 2 years is
49% (95% CI: 38-60) with a median follow up of 19 months.
These results indicate that the co-infusion of two partially HLA
matched UCB units after myeloablative or non-myeloablative con-
ditioning results in a high incidence of engraftment, and low rates
of AGVHD, CGVHD and TRM. Randomized trials are required
to determine the relative beneﬁt of double UCBT as compared to
single UCBT or transplantation of HLA matched marrow.
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DOUBLE CORD BLOOD TRANSPLANTATION IN ADULTS USING A
REDUCED INTENSITY CHEMOTHERAPY ONLY CONDITIONING REGIMEN
Ballen, Karen. Masachusetts General Hospital.
Umbilical cord blood is a useful stem cell source for patients
without matched donors. Adult cord blood transplantation is lim-
ited by the low cell dose in most individual cord blood units. Initial
studies using single cord blood units with a myeloablative condi-
tioning regimen reported a 100 day transplant related mortality of
over 40%. Double cord blood transplantation (two units adminis-
tered sequentially) provides a higher cell dose, and a reduced
intensity conditioning regimen may decrease transplant related
mortality.
We have treated 35 patients with this approach using a conditioning
regimen of ﬂudarabine 30 mg/m2/day days8 through3 (total dose
180 mg/m2), melphalan 100 mg/m2 day2 and rabbit antithymocyte
globulin 1.5 mg/kg days 7, 5, 3, 1 (total dose 6 mg/kg). Cord
blood units were a 4/6 or higher HLA A, B, DR allele match with the
patient and each other and achieved a minimum precryopreservation
cell dose of 3.7  107 NC/kg. Twenty one patients received GVHD
prophylaxis with cyclosporine and mycophenolate mofetil and four-
teen patients received GVHD prophylaxis with tacrolimus and siroli-
mus. Only ﬁve patients treated with sirolimus and tacrolimus have
greater than 100 days of follow up; the results with this GVHD
regimen will be reported subsequently.
For the cyclosporine/mycophenolate mofetil patients the median
days to neutrophil and platelet engraftment (platelet count greater
than 20,000 unsupported) were 20 and 41 days respectively. Fifteen of
21 patients are alive with a median follow up of 16 months. One
patient with CLL has progressive disease. The 100 day transplant
related mortality is 14%, with the deaths from post-transplant lym-
phoproliferative disorder, central nervous system bleeding, and staph-
ylococcal sepsis. One year disease free survival is 66%. Double cord
blood transplantation with a reduced intensity regimen may be a safer
option for patients requiring cord blood transplantation.
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RISK OF RELAPSE AFTER UMBILICAL CORD BLOOD TRANSPLANTATION
IN PATIENTS WITH ACUTE LEUKEMIA: MARKED REDUCTION IN
RECIPIENTS OF TWO UNITS
Verneris, Michael R., Brunstein, Claudio, DeFor, Todd E.,
Barker, Juliet, Weisdorf, Daniel J., Blazar, Bruce R., Miller, Jeffrey S.,
Wagner, John E. Blood & Marrow Transplant Program, University of
Minnesota, Minneapolis, MN.
We analyzed patients with acute leukemia transplanted with
myeloablative conditioning at a single institution to determine if
there were any unique risk factors associated with relapse after
UCBT. Ninety-six consecutive patients were evaluated, 39 were
18 years of age, 50 were male; 46 were CMV seropositive; 50
had ALL and 46 had AML. Two different conditioning regi-
mens were used. Regimen A consisted of cyclophosphamide 120
mg/kg, TBI 1320-1375 cGy, and ATG, followed by cyclospor-
ine A (CSA)/methylprednisolone immunosuppression (n  53).
Regimen B consisted of cyclophosphamide 120 mg/kg, ﬂudara-
bine 75 mg/m2, TBI 1320-1375 cGy pre-transplant and CSA/
mycophenolate mofetil immunosuppression (n  43). Patients
received either one (n  67) or two (n  29) 4-6/6 HLA-
matched UCB units, so that the total IVCNC count was 2.5 
107/kg. Accordingly, the demographics for recipients of one or
two UCB units were similar except for older age (median age 24
vs 8, P  0.01) and greater weight (median 70 vs 32 kg, P 
0.01) for recipients of two UCB units. Potential risk factors for
relapse that were evaluated included: age, gender, recipient
CMV sero-status, diagnosis, disease risk, HLA disparity, regi-
men (A vs B), and TNC (or CD34) dose of the unit responsible
for sustained engraftment.
Notably, in Cox regression analysis two factors were associated
with lower relapse risk: disease risk (CR1/CR2 vs CR3/REL [RR
0.32, P  0.02]) and transplantation of two UCB units (RR 0.3,
P  0.03). Importantly, the diagnosis, UCB graft cell dose, and
presence of acute GVHD had no demonstrable impact. All recip-
ients of regimen A received a single UCB unit (relapse was 28%
(95% CI, 15-41%)), thus interactions between regimen A and
number of UCB units could not be assessed. Patients who received
regimen B in CR1/2, showed a signiﬁcantly lower risk of relapse
with two UCB units compared to one unit (11% vs 54%, P 0.01).
No signiﬁcant difference in relapse risk could be discerned for
patients with advanced disease (CR3-REL) when comparing single
vs double UCBT (P  0.48).
This report is the ﬁrst suggesting that double unit UCB grafts
may be associated with reduced relapse risk in acute leukemia.
Larger studies are needed to conﬁrm this clinical experience and to
investigate the potential mechanisms by which double unit grafts
could mediate protection against relapse.
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MYELOABLATIVE SINGLE CORD TRANSPLANTS (SCT) VERSUS DUAL
CORD TRANSPLANTS (DCT) IN ADULTS WITH ACUTE LEUKEMIA
Wooford, Jonathan, Regan, Donna, Alonso, Mario, Creer, Michael H.
St. Louis Cord Blood Bank and Departments of Pathology/Lab Medicine
and Pediatrics, St. Louis University, St. Louis, MO.
Background: Combining 2 cord blood products overcomes the
total nucleated cell (TNC) dose limitation and may improve clin-
ical outcomes following allogeneic cord blood (CB) transplantation
in adults. We performed a retrospective case-control study in adult
patients with acute leukemia receiving myeloablative conditioning
and 1 or 2 cord blood units to identify potential causes for differ-
ences in clinical outcomes following SCT and DCT and product
characteristics predictive of long-term engraftment in DCT recip-
ients.
Study design: To evaluate 20 DCT cases, we selected 20 SCT
with the largest TNC dose as controls from a cohort of 103 adult
SCT patients. SCT and DCT were matched for age, sex, diagnosis,
disease status, ethnicity and body weight (0.11  P  0.78) ex-
cluding patients with graft failure or previous transplants.
Results: Administered TNC dose for DCT (3.7  107/kg) was
nearly 2-fold greater than SCT (1.9 107/kg, P 0.0001) with no
signiﬁcant differences in post-thaw TNC recovery (P  0.13).
Time to ANC500/uL for DCT was 17 days compared to 20 days
for SCT (P  0.02). For SCT, there were 9 and 11 patients with
1 or 2 Ag mismatch at HLA-A,B or DRB1, respectively, (mean 
1.6 Ag mismatch). Three-way comparison of both donors and
recipient for DCT also gave mean  1.6 Ag mismatch. Overall
survival (OS) at 12 months was 18% for SCT and 72% for DCT
(P 0.0001) with median duration of follow-up of18 months for
both SCT and DCT. OS was signiﬁcantly correlated with post-
thaw TNC dose for SCT (P  0.04) but not for DCT (P  0.88).
In the ﬁrst 100 days post-transplant, infection rates for SCT (65%)
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